Pre-market hot trades in US stocks: Airship AI pre-market down 10.42%; Bitdeer Tech pre-market down 10.23%

Pre-market Hot Trades in US Stocks Airship AI, down 10.42% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Bitdeer Tech is down 10.23% in pre-market trading. Based on recent key news: On January 19, Bitdeer Technologies Group announced its production and operational results for December 2025, showing a 339% year-on-year increase in Bitcoin mining volume, reaching 636 coins. Bitcoin price fluctuations may affect the stock price. Source: BlockBeats On January 20, the market sentiment index fell from the extreme bullish range to below neutral, marking a shift in market structure and a deterioration in risk quality, leading to a decline in Bitcoin prices. Source: BlockBeats On January 20, a whale address attempted to bottom-fish after consecutive liquidations but soon closed positions, indicating increased market volatility. Source: BlockBeats The cryptocurrency market is experiencing heightened volatility, and risks should be monitored. Top Gainers in Pre-market US Stocks INVO Fertility, up 423.14% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. Icon Energy, up 134.54% in pre-market trading, has no significant recent news. Trading is active with clear capital flows, and considering sector and industry trends, the stock shows significant volatility, with specific reasons needing further observation. RAPT is up 63.53% in pre-market trading. Based on recent key news: On January 20, GSK announced its acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's stock price up 63.53% in pre-market trading. GSK will acquire RAPT at a price of $58 per share and gain global rights to its experimental food allergy drug ozureprubart. This move expands GSK's respiratory, immunology, and inflammation product lines. Source: Reuters On January 20, GSK's Chief Scientific Officer Tony Wood stated that ozureprubart is expected to become a best-in-class treatment, providing sustained protection every 12 weeks. This news further bolstered market confidence in RAPT. Source: Dow Jones Newswires On January 20, analysts rated GSK stock as a moderate sell; although RAPT's acquisition is favorable for GSK's strategy, the market remains cautious about GSK's stock price. Source: MT Newswires The biotechnology industry is experiencing frequent M&A activity, with significant capital inflows